CRYOLIFE INC (CRY) Stock Price, Forecast & Analysis
USA - NYSE:CRY - Common Stock
CRY Key Statistics, Chart & Performance
The current stock price of CRY is 17.88 null. In the past month the price decreased by -10.29%. In the past year, price decreased by -29.19%.
CRY Latest News, Press Relases and Analysis
CRY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.17 | 227.29B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.82 | 196.99B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.81 | 152.16B | ||
| SYK | STRYKER CORP | 27.5 | 138.48B | ||
| BDX | BECTON DICKINSON AND CO | 13.39 | 55.33B | ||
| IDXX | IDEXX LABORATORIES INC | 54.71 | 55.19B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.58 | 50.67B | ||
| RMD | RESMED INC | 24.69 | 35.68B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.94 | 33.40B | ||
| PODD | INSULET CORP | 72.8 | 23.42B | ||
| DXCM | DEXCOM INC | 31.22 | 22.77B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.11 | 17.81B |
Related stock screener links
About CRY
Company Profile
CryoLife, Inc. engages in the manufacture, process and distribution of medical devices. The company is headquartered in Kennesaw, Georgia and currently employs 1,200 full-time employees. The firm is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The firm operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as Surgical Sealants, BioGlue products, JOTEC products, On-X products, CardioGenesis cardiac laser therapy, PhotoFix, and NEXUS. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues.
Company Info
CRYOLIFE INC
1655 Roberts Blvd NW
Kennesaw GEORGIA 30144 US
CEO: J. Patrick Mackin
Employees: 1200
Phone: 17704193355.0
CRYOLIFE INC / CRY FAQ
What does CRY do?
CryoLife, Inc. engages in the manufacture, process and distribution of medical devices. The company is headquartered in Kennesaw, Georgia and currently employs 1,200 full-time employees. The firm is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The firm operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as Surgical Sealants, BioGlue products, JOTEC products, On-X products, CardioGenesis cardiac laser therapy, PhotoFix, and NEXUS. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues.
What is the current price of CRY stock?
The current stock price of CRY is 17.88 null. The price increased by 1.42% in the last trading session.
Does CRYOLIFE INC pay dividends?
CRY does not pay a dividend.
What is the ChartMill rating of CRYOLIFE INC stock?
CRY has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the analyst forecast for CRY stock?
8 analysts have analysed CRY and the average price target is 33.09 null. This implies a price increase of 85.05% is expected in the next year compared to the current price of 17.88.
Is CRYOLIFE INC (CRY) expected to grow?
The Revenue of CRYOLIFE INC (CRY) is expected to grow by 18.02% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the upcoming earnings date for CRYOLIFE INC?
CRYOLIFE INC (CRY) will report earnings on 2022-02-10.
CRY Technical Analysis
CRY Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CRY. There are concerns on the financial health of CRY while its profitability can be described as average.
CRY Financial Highlights
Over the last trailing twelve months CRY reported a non-GAAP Earnings per Share(EPS) of 0.3. The EPS increased by 130.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -0.37% | ||
| ROA | -0.16% | ||
| ROE | N/A | ||
| Debt/Equity | 1 |
CRY Forecast & Estimates
8 analysts have analysed CRY and the average price target is 33.09 null. This implies a price increase of 85.05% is expected in the next year compared to the current price of 17.88.
For the next year, analysts expect an EPS growth of -91.22% and a revenue growth 18.02% for CRY